Cronos Group Inc

Analysts expect Altria to report revenues of $5.08 billion in the second quarter of 2020—a fall of 2.2% from $5.19 billion in the second quarter of 2019.

New Approach Montana resumed its marijuana legalization campaign in May. The group submitted plenty of signatures and qualified for the November ballot.

OrganiGram (NASDAQ:OGI) stock is trading higher before its third-quarter earnings. The stock closed with a gain of 3.9% at $1.58 on Wednesday.

Charlotte’s Web Holdings (NYSEARCA:CWEB) is one of the main players in the CBD business. The company plans to keep expanding in 2020.

Today, Gaurav Jain of Barclays downgraded Altria Group (NYSE:MO) from “overweight” to “equal weight.” He also lowered his target price from $50 to $43.

On June 30, Innovative Industrial Properties announced its decision to raise additional capital of $225 million through a public offering of its common stock.

OrganiGram will likely report its earnings for the third quarter of fiscal 2020 on July 13. We’ll have to see if marijuana stocks recover in July.

On Monday, Cantech Letter reported that Raymond James downgraded OrganiGram from an “outperform” rating to a “market perform” rating.

Earlier this week, Rahul Sarugaser of Raymond James upgraded Cronos Group (NASDAQ:CRON) from “market perform” to “outperform.”

Aurora Cannabis (NYSE:ACB) announced some business transformation plans on June 23. The plans included cost savings and margin improvement.

Marijuana legalization in South Dakota could see daylight in 2020. The state passed measures to legalize both recreational and medical marijuana.

While most businesses suffered amid COVID-19, marijuana saw a drastic rise in sales. Many states have been rethinking the benefits of marijuana legalization.

Hexo beat the revenue estimates of 19.9 million Canadian dollars. However, the company reported a quarterly EBITDA loss of 4.3 million Canadian dollars.

Lorne Steinberg thinks that even after Hexo’s deal with Molson Coors, it still doesn’t look attractive. He would rather find value somewhere else.

Layoffs amid COVID-19 led to a decline in disposable income, which had a negative impact on the cigarette and cannabis industries.

So far this year, Philip Morris International (NYSE:PM) and Altria Group (NYSE:MO) have underperformed the broader equity markets.

Canopy Growth (NYSE:CGC)(TSE:WEED) still has investors’ attention despite all that the marijuana industry has gone through.

Tilray (NASDAQ:TLRY) posted its first-quarter earnings on May 11. The revenue growth was impressive in the first quarter.

On April 7, the NYSE sent a listing notification to Hexo. The warning said that the stock fell below the NYSE’s $1.00 share price continued listing standard.

Aurora Cannabis (NYSE:ACB) reported its third-quarter results on May 14. The earnings report was a surprise for most analysts and investors.

Aurora Cannabis saw less of an impact from COVID-19 in the third quarter. Cannabis is an essential item amid the pandemic.

Marijuana companies in the US have been struggling to get financial and banking access. Cannabis still isn’t legal at the federal level.

Green Thumb Industries (OTCMKTS:GTBIF) will likely report its results for the first quarter of fiscal 2020 on May 14 after the market closes. 

Cronos Group (NASDAQ:CRON) reported its results for the first quarter of fiscal 2020 on May 8. The revenue growth was stronger.

Aurora Cannabis (NYSE:ACB) announced a reverse stock split in April. The stock split happened on Monday and the stock took a hit.

Cronos Group (NASDAQ:CRON) reported its results for the first quarter of fiscal 2020 on May 8. The revenue improved from the fourth quarter of fiscal 2019.

On May 8, Aphria’s (NYSE:APHA) management announced that it agreed to repurchase its convertible senior notes from some holders outside of Canada.

In New Zealand, marijuana legalization’s fate depends on the September general elections. The country has a final bill to put on the ballot.

The meltdown in global financial markets amid COVID-19 dragged Tilray stock down to $2.43 on March 18. Since then, the stock has recovered.

Today, Aphria (NYSE:APHA) announced that ASG Pharma has received EU GMP certification to produce cannabis for medical and research purposes.

Cronos Group (NASDAQ:CRON) will likely report its results for the first quarter of fiscal 2020 on May 8 before the market opens.

Marijuana campaigns have struggled to gather signatures amid the coronavirus pandemic. However, there’s still some hope in Nebraska.

Constellation Brands (NYSE:STZ) expressed its confidence in Canopy Growth (NYSE:CGC)(TSE:WEED) by increasing its stake in the company.

As of April 29, Cronos Group was trading at 8.63 Canadian dollars—a fall of 4.3% since the company reported its fourth-quarter earnings.

Currently, 14 analysts cover Altria stock. Many analysts have a bullish view on the stock due to its higher dividend yield and lower valuation.

Marijuana legalization laws have failed numerous times in New Jersey. There’s a lot of support to legalize recreational cannabis in the state.

The marijuana legalization topic might not have ended completely in New York. Governor Cuomo thinks that lawmakers might pass the legislation remotely.

On April 14, Aphria (NYSE:APHA) reported its third-quarter earnings. For the quarter, the company reported revenues of 144.4 million Canadian dollars.

Jefferies went bullish on Aphria and bearish on Tilray. Notably, Tilray stock fell 6% on Thursday after Jefferies downgraded the stock.

OrganiGram’s second-quarter results didn’t meet the expectations. Many analysts downgraded the stock and cut the target price.

OrganiGram (NASDAQ:OGI) reported its results for the second quarter of fiscal 2020 on April 14 before the market opened. The results weren’t impressive.

On Tuesday, Aphria (NYSE:APHA) reported its third-quarter results. The company reported impressive third-quarter results and beat analysts’ expectations.

Washington has included cannabis on the list of essential items. However, the COVID-19 crisis has caused the state to make some strict changes.

OrganiGram will report its results for the second quarter of fiscal 2020 on April 14 before the market opens. Analysts aren’t hopeful about the results.

Marijuana is gaining a lot of attention amid the coronavirus pandemic. Many people think that Joe Biden should support marijuana legalization.

KushCo’s second-quarter revenue was almost in line with analysts’ estimates. The company reported revenue of $30.14 million.

Analysts expect Aphria to report revenue of 130.6 million Canadian dollars in the third quarter—growth of 77.5% YoY and a sequential increase of 8.3%.

Analysts have lowered the revenue estimates for OrganiGram for fiscal 2020. Analysts expect the revenue to be around 127 million Canadian dollars.

Hexo stock fell to a low of 0.68 Canadian dollars and closed Wednesday at 0.71 Canadian dollars. The stock fell by 26% from Tuesday’s closing price.

Despite increased sales, the marijuana industry’s struggles haven’t ended. Temporarily closing stores and laying off employees will take a toll.

Tilray (NASDAQ:TLRY) had a disastrous 2019—the stock lost 75.7% of its value. So far, 2020 hasn’t been pretty either for the stock.

Marijuana provides employment opportunities and tax revenue to the states. However, cannabis companies don’t get federal business relief during COVID-19.

Cronos Group disappointed analysts and investors with its results for the fourth quarter of fiscal 2019. The company missed analysts’ revenue estimates.

On April 6, Bruce Linton said that Canopy Growth (TSE:WEED) and Cronos Group (NASDAQ:CRON) are better equipped to withstand the COVID-19 storm.

North Dakota has struggled to gather signatures amid the coronavirus outbreak. As a result, the state suspended its marijuana legalization campaign.

As of April 3, Aurora Cannabis stock has fallen 10%, while Canopy Growth has fallen 8.1%. Cronos Group and Hexo have fallen 2.6% and 19.3% in April.

Medical marijuana legalization won’t happen in Idaho in 2020 due to the coronavirus pandemic. The ICC couldn’t gather the required signatures.

New York lawmakers decided to delay marijuana legalization due to the COVID-19 pandemic. As a result, New York won’t see marijuana legalization in 2020.

Cannabis sales continue to rise due to increased demand amid the coronavirus outbreak. Globally, the coronavirus chaos has caused panic and anxiety.

Cronos Group (NASDAQ:CRON) disappointed investors with its fourth-quarter results on March 30. The company’s revenue was way below analysts’ estimates.

MedMen stock fell by 12.0% on March 30 after the company released some corporate updates. MedMen has been struggling with a cash crunch.

Cronos Group reported its fourth-quarter and fiscal 2019 results on Monday after the market closed. The company’s fourth-quarter results were disappointing.

Cronos Group will report its fourth-quarter and fiscal 2019 results after the market closes today—a delay from the original date of February 27.

Marijuana legalization efforts in the US have slowed down because of the coronavirus outbreak. Missouri was determined to legalize marijuana in 2020.

Hexo (TSE:HEXO) stock closed 41.3% higher on March 26. So far this week, the stock has risen 59.2%. Hexo faced getting delisted from the exchange.

Last week was the worst week since October 2008. However, the cannabis sector fared better than the broader equity markets.

Hexo (TSE:HEXO) closed with a loss of 19% on March 18. The stock started its downward trend on Tuesday. The company decided to delay its second-quarter earnings.

On Tuesday, Canopy Growth (NYSE:CGC)(TSE:WEED) announced that it will temporarily close all of its company-owned Tokyo Smoke and Tweed retail stores.

On Monday, Aurora Cannabis (NYSE:ACB) announced that its founder and former CEO, Terry Booth, sold approximately 12.2 million shares in the open market.

Hexo (TSE:HEXO) has been struggling for a while now. The string of bad news started in October 2019 when CFO Michael Monahan resigned.

Sundial Growers isn’t a big name in the cannabis sector. However, the company has a variety of cannabis products, which earned it a name in the space.

On Thursday, WBRC reported that the Alabama Senate cleared Senate Bill 165. The bill will create the Compassion Act, which legalizes medical marijuana.

Aurora Cannabis (NYSE:ACB) stock has fallen below $1 on the NYSE, which puts it at the risk of being delisted from the exchange.

Recently, the UN questioned whether marijuana legalization has benefited Canada. The Canadian government defended its position.

Canopy Growth (NYSE:CGC)(TSE:WEED) has lost 33.9% of its stock value this year. So, did yesterday’s fall make the stock an attractive buy?

The marijuana legalization process in US states is speeding up in 2020. Many new states are coming up with their own proposals to legalize marijuana.

As of March 6, Altria Group (NYSE:MO) was trading at $42.15—a fall of 15.9% since the company reported its earnings for the fourth quarter of 2020 on January 30.

Marijuana became legal in Illinois on January 1, 2020. As expected, retail cannabis sales started soaring as soon as legal shops opened their doors.

MKM Partners analyst Bill Kirk likes Cronos Group’s healthy cash position, strong track record, and its relationship with Altria (NYSE:MO).

Cannabis companies that have operations in China, especially the ones that manufacture vape products, have been impacted by the coronavirus.

As of February 28, OrganiGram Holdings (NASDAQ:OGI) was trading at 2.98 Canadian dollars—a fall of 6.6% since the beginning of this year.

As of February 28, Canopy Growth (NYSE:CGC)(TSE:WEED) was trading at 25.17 Canadian dollars. So far, the company has lost 7.8% of its stock value YTD.

Cronos Group was going to report its Q4 earnings before the market opens on Thursday. However, the company announced a delay in its earnings release.

On Monday, MarketWatch reported that Cowen downgraded Aurora Cannabis from “outperform” to “market perform” and lowered the target price.

On February 21, HEXO fell to a low of 1.40 Canadian dollars and closed at 1.41 Canadian dollars. The stock fell 2.1% from the previous day’s closing price.

Cronos Group will report its fourth-quarter earnings before the market opens on Thursday. Analysts expect double-digit revenue growth sequentially.

President Trump’s re-election campaign spokesperson said that the administration thinks that marijuana and other drugs should be illegal.

Jason Zandberg of PI Financial reiterated its “buy” rating for Cronos Group. He also maintained his target price of 17 Canadian dollars for the stock.

Aurora Cannabis reported its results for the second quarter of fiscal 2020 on February 13. The company reported revenues of 56.0 million Canadian dollars.

Mexico might finally see cannabis legalization by the end of this month. The Mexico Supreme Court extended the deadline to April 30.

For the second quarter, Aurora Cannabis reported net revenues of 56.0 million Canadian dollars, which fell short of analysts’ expectations.

Aurora Cannabis (NYSE:ACB) will report its results for the second quarter of fiscal 2020 today before the market opens. Investors will be watching closely.

Aurora Cannabis will likely report its Q2 results on Thursday before the market opens. In the last two weeks, the company delivered disappointing news.

AGLC will allow retail stores in Alberta to sell marijuana vape products. Consumers will likely be able to purchase cannabis vape products in the next two weeks.

Aurora Cannabis started 2020 with a lot of bad news. The company announced job cuts last week, which impacted its profitability.

Some countries still have very strict marijuana laws. Recently, Singapore’s government asked Netflix to block all marijuana shows and films in the country.

Canopy Growth will report its earnings for the third quarter of fiscal 2020 before the market opens on Friday. Analysts expect the revenue to rise.

More Kentucky residents favor marijuana legalization. According to a poll, 90% of the respondents favor medical marijuana compared to 78% in 2012.

ACB provided unaudited preliminary results for its second-quarter earnings on Thursday. The cannabis revenue could be 62 million–66 million Canadian dollars.